Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategies
Open Access
- 27 April 2022
- journal article
- other
- Published by Taylor & Francis in Expert Review of Proteomics
- Vol. 19 (2) , 115-129
Abstract
Drug resistance is the main barrier to achieving cancer cures with medical therapy. Cancer drug resistance occurs, in part, due to adaptation of the tumor and microenvironment to therapeutic stress...Keywords
Funding Information
- Miriam and Sheldon Adelson Medical Research Foundation
This publication has 147 references indexed in Scilit:
- Progression of RAS-Mutant Leukemia during RAF Inhibitor TreatmentNew England Journal of Medicine, 2012
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast CancerCancer Discovery, 2012
- The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancersNature, 2012
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast CancerCell, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 2010
- Serial dilution curve: a new method for analysis of reverse phase protein array dataBioinformatics, 2009
- Mutations of the BRAF gene in human cancerNature, 2002